Contraception
Volume 79, Issue 6 , Pages 433-438 , June 2009

A nationwide cohort study of the use of the levonorgestrel intrauterine device in New Zealand adolescents

  • Helen Paterson

      Affiliations

    • Dunedin School of Medicine, Department of Women's and Children's Health, University of Otago Dunedin 9054, New Zealand
    • Corresponding Author InformationCorresponding author. Tel.: +64 3 4797185; fax: +64 3 4770509.
    • ,
  • Janelle Ashton

      Affiliations

    • Department of Preventive and Social Medicine, Intensive Monitoring Programme (IMMP), University of Otago, Dunedin 9054, New Zealand
    • ,
  • Mira Harrison-Woolrych

      Affiliations

    • Department of Preventive and Social Medicine, Intensive Monitoring Programme (IMMP), University of Otago, Dunedin 9054, New Zealand

Received 11 August 2008 ,Revised 30 November 2008 ,Accepted 1 December 2008.

References 

  1. WHO . Medical eligibility criteria for contraceptive use—3rd edition. Effectiveness of method. Geneva: WHO; 2004;
  2. Hubacher D. Copper intrauterine device use by nulliparous women: review of side effects. Contraception. 2007;75(Suppl):S8–S11
  3. Lacy J. Clinic opinions regarding IUCD use in adolescents. J Pediatr Adolesc Gynecol. 2006;19:301–303
  4. Mohllajee AP, Curtis KM, Peterson HB. Does insertion and use of an intrauterine device increase the risk of pelvic inflammatory disease among women with sexually transmitted infection? A systematic review. Contraception. 2006;73:145–153
  5. Prager S, Darney PD. The levonorgestrel intrauterine system in nulliparous women. Contraception. 2007;75(Suppl):S12–S15
  6. Hubacher D, Lara-Ricalde R, Taylor DJ, Guerra-Infante F, Guzman-Rodriguez R. Use of copper intrauterine devices and the risk of tubal infertility among nulligravid women. N Engl J Med. 2001;345:561–567
  7. ACOG . ACOG Committee Opinion No. 392, December 2007. Intrauterine device and adolescents. Obstet Gynecol. 2007;110:1493–1495
  8. Harrison-Woolrych M, Coulter DM. PEM in New Zealand. In:  Mann R,  Andrews EB editor. Pharmacovigilance. 2nd ed. Chichester: John Wiley and Sons Ltd; 2006;p. 313–328
  9. Coulter DM. The New Zealand Intensive Medicines Monitoring Programme. Pharmacoepidemiol Drug Saf. 1998;7:79–90
  10. Coulter D. PEM in New Zealand. Pharmacovigilance. 2002;345–362
  11. Harrison-Woolrych M, Ashton J, Coulter D. Insertion of the Multiload Cu375 intrauterine device; experience in over 16,000 New Zealand women. Contraception. 2002;66(6):387–391
  12. Harrison-Woolrych M, Zhou L, Coulter D. Insertion of intrauterine devices: a comparison of experience with Mirena and Multiload Cu 375 during post-marketing monitoring in New Zealand. N Z Med J. 2003;116(1179):U538
  13. Zhou L, Harrison-Woolrych M, Coulter DM. Use of the New Zealand Intensive Medicines Monitoring Programme to study the levonorgestrel-releasing intrauterine device (Mirena). Pharmacoepidemiol Drug Saf. 2003;12:371–377
  14. Paterson H, Miller D, Devenish C. Survey of RANZCOG Fellows practising in New Zealand and their use of intrauterine levonorgestrel-releasing system in adolescents. ANZJOG. 2008;48:112–118
  15. Bahamondes L, Petta CA, Fernandes A, Monteiro I. Use of the levonorgestrel-releasing intrauterine system in women with endometriosis, chronic pelvic pain and dysmenorrhea. Contraception. 2007;75(Suppl):S134–S139
  16. French L. Dysmenorrhea. Am Fam Physician. 2005;71:285–291
  17. Suhonen S, Haukkamaa M, Jakobsson T, Rauramo I. Clinical performance of a levonorgestrel-releasing intrauterine system and oral contraceptives in young nulliparous women: a comparative study. Contraception. 2004;69:407–412
  18. Paransky OI, Zurawin RK. Management of menstrual problems and contraception in adolescents with mental retardation: a medical, legal, and ethical review with new suggested guidelines. J Pediatr Adolesc Gynecol. 2003;16:223–235
  19. Albanese A, Hopper NW. Suppression of menstruation in adolescents with severe learning disabilities. Arch Dis Child. 2007;92:629–632
  20. Atkinson E, Bennett MJ, Dudley J, et al. Consensus statement: menstrual and contraceptive management in women with an intellectual disability. ANZJOG. 2003;43:109–110
  21. Cundy T, Cornish J, Roberts H, Elder H, Reid IR. Spinal bone density in women using depot medroxyprogesterone contraception. Obstet Gynecol. 1998;92(4 Pt 1):569–573
  22. Cromer BA, Scholes D, Berenson A, Cundy T, Clark MK, Kaunitz AM. Depot medroxyprogesterone acetate and bone mineral density in adolescents — the Black Box Warning: a Position Paper of the Society for Adolescent Medicine. J Adolesc Health. 2006;39:296–301
  23. Ministry of Health . Sexual and reproductive health: a resource book for New Zealand health care organisations. Wellington: Ministry of Health; 2003;
  24. Backman T. Benefit–risk assessment of the levonorgestrel intrauterine system in contraception. Drug Saf. 2004;27:1185–1204
  25. Weiner E, Berg A, Johansson I. Copper intrauterine contraceptive devices in adolescent nulliparae. BJOG. 1978;85:204–206
  26. Zibners A, Cromer BA, Hayes J. Comparison of continuation rates for hormonal contraception among adolescents. J Pediatr Adolesc Gynecol. 1999;12(2):90–94
  27. McNaught J. Adolescents and IUCDs — not a contraindication. J Pediatr Adolesc Gynecol. 2006;19:303–305

PII: S0010-7824(08)00550-7

doi: 10.1016/j.contraception.2008.12.001

Contraception
Volume 79, Issue 6 , Pages 433-438 , June 2009

Article Tools

* Image Usage & Resolution